Establishing an hTERT-driven immortalized umbilical cord-derived mesenchymal stem cell line and its therapeutic application in mice with liver failure
Quick Facts
- Publication title: Establishing an hTERT-driven immortalized umbilical cord-derived mesenchymal stem cell line and its therapeutic application in mice with liver failure
- Journal: J Tissue Eng
- Year: 2023
- DOI: 10.1177/20417314231200328
- PMID/PMCID: 37736245; PMC10510347
Research overview
Acute liver failure (ALF) is characterized by rapid liver cell destruction. Inoculation of hTERT-UCMSC and its exosomes could potentially be used in clinics for the treatment of liver failure in the future.
Key findings
Acute liver failure (ALF) is characterized by rapid liver cell destruction.
It is a multi-etiological and fulminant complication with a clinical mortality of over 80%.
Therapy using mesenchymal stem cells (MSCs) or MSCs-derived exosomes can alleviate acute liver injury, which has been demonstrated in animal experiments and clinical application.
However, similar to other stem cells, different cell sources, poor stability, cell senescence and other factors limit the clinical application of MSCs.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Establishing an hTERT-driven immortalized umbilical cord-derived mesenchymal stem cell line and its therapeutic application in mice with liver failure J Tissue Eng. 2023. DOI: 10.1177/20417314231200328. PMID/PMCID: 37736245; PMC10510347.